Eteplirsen
Composition
This formulation contain Eteplirsen as active agent
Indications
the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the dystrophin gene
Side effects
balance disorders, vomiting, and upper respiratory tract infections
Precautions
Patients should be monitored for signs of kidney toxicity and hypersensitivity reactions during treatment
Contraindications
Contraindications include known hypersensitivity to eteplirsen or any of its components
Dosage and administration
directed by a healthcare professional
Countries
Available Forms
Injection
Manufacturing Services
Third Party Manufacturing Company WHO, GMP, EUGMP, USFDA, In India | Contract Manufacturing Organization (CMO) WHO, GMP, EUGMP, USFDA Services in India, Mumbai, Navi Mumbai| Contract Development and Manufacturing Organization (CDMO) WHO, GMP, EUGMP, USFDA - Services in India | Pharmaceutical Contract Manufacturing Company WHO, GMP, EUGMP, USFDA in Navi Mumbai, India | Top Pharmaceutical Product Exporters, Suppliers, Distributer WHO, GMP, EUGMP, USFDA in Mumbai